You are not currently logged in.
Access JSTOR through your library or other institution:
Live Subgroup B Respiratory Syncytial Virus Vaccines That Are Attenuated, Genetically Stable, and Immunogenic in Rodents and Nonhuman Primates
James E. Crowe Jr., Phuong T. Bui, Cai-Yen Firestone, Mark Connors, William R. Elkins, Robert M. Chanock and Brian R. Murphy
The Journal of Infectious Diseases
Vol. 173, No. 4 (Apr., 1996), pp. 829-839
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30132585
Page Count: 11
You can always find the topics here!Topics: Viruses, Vero cells, Transcriptional regulatory elements, Human respiratory syncytial virus, Cotton, Vaccination, Genetic mutation, Infections, Cultured cells, Phenotypes
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Optimal immunization of neonates against disease caused by respiratory syncytial virus (RSV) probably will require multiple doses of a vaccine containing viruses of both subgroups A and B. Live subgroup B RSV mutants were generated containing multiple attenuating mutations, ts (temperature-sensitive) and non-ts (host range), that were introduced by prolonged passage in cell culture or by chemical mutagenesis. The cold-passaged (cp)-52 mutant was restricted in replication compared to wild type virus in rodents and nonhuman primates. In addition, the attenuation phenotype of cp-52 was stable after prolonged replication in immunosuppressed rodents. One or two ts mutations were then introduced into the cp-52 mutant to generate additional candidate vaccine strains that were more attenuated in vivo than the cp-52 parental virus. Tests in humans are being done to determine if one or more of the RSV B-l mutants exhibit a satisfactory balance between attenuation and immunogenicity.
The Journal of Infectious Diseases © 1996 Oxford University Press